Merck & Company (MRK) : The total money flow in Merck & Company (MRK) was negative ($4.76 million), which signals selling by the traders on Fridays session. They trimmed their holdings by selling the stock on downticks to the tune of $86.05 million. In comparison, the inflow of money into the stock on upticks was $81.3 million. The uptick to downtick ratio was 0.94. Similarly, the block trades show selling by large traders on strength. The value of stocks sold down on downtick was $29.48 million. The value of transactions on uptick was $21.06 million. The negative money flow of ($8.42 million) confirms the selling in Merck & Company (MRK) on strength. The uptick to downtick ratio of block trades was 0.71. Merck & Company (MRK) gained $0.08 at $62.98, a gain of 0.13% over the previous days close. However, the stock registered 0.21% in the week.
The company Insiders own 0.05% of Merck & Company shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -32.16% . Institutional Investors own 73.24% of Merck & Company shares. During last six month period, the net percent change held by insiders has seen a change of -32.72%.
In a related news, The Securities and Exchange Commission has divulged that Schechter Adam H, officer (EVP & Pres-Global Human Health) of Merck & Co., Inc., had unloaded 39,200 shares at an average price of $62.61 in a transaction dated on September 1, 2016. The total value of the transaction was worth $2,454,312.
Merck & Company (NYSE:MRK): The stock opened at $62.59 and touched an intraday high of $63.27 on Friday. During the day, the stock corrected to an intraday low of $62.59, however, the bulls stepped in and pushed the price higher to close in the green at $62.98 with a gain of 0.13% for the day. The total traded volume for the day was 7,613,244. The stock had closed at $62.9 in the previous trading session.
Merck & Company (MRK) : During the past 4 weeks, traders have been relatively bearish on Merck & Company (MRK), hence the stock is down -1.25% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.3% relative to the S&P 500. The stock has risen by 0.21% in the past week indicating that the buyers are active at lower levels, but the stock is down -1.38% in the past 4 weeks.
Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. The Companys animal health products are sold to veterinarians, distributors and animal producers.